https://www.selleckchem.com/pr....oducts/oprozomib-onx
366) with placebo and -0.13 nmol/L (0.244) with albiglutide. For the primary Bayesian analysis (including prior study data) the posterior treatment difference (95% credible interval) was estimated at 0.12 nmol/L (0-0.24);the probability of a difference ≥0.2 nmol/L between treatments was low (0.097). A transient significant difference in maximum C-peptide was seen at week 28. Otherwise, no significant secondary endpoint differences were noted. . On-therapy adverse events were reported in 82.0% (albiglutide) and 76.5% (placebo)
Like
Comment
Share
